Therapeutic applications of nucleic acids and their analogues in toll-like receptor signaling

Molecules

Volumn 17, Issue 11, 2012, Pages 13503-13529

  Gosu, Vijayakumar ^a   Basith, Shaherin ^a   Kwon, O Pil ^a   Choi, Sangdun ^a  

^a Ajou University   (South Korea)

Author keywords

Autoimmune disease; Cancer; Clinical status; Nucleic acid analogues; Toll like receptor; Viral infection

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AUTACOID; CYTOKINE; IMMUNOLOGIC FACTOR; NUCLEIC ACID; NUCLEOSIDE; TOLL LIKE RECEPTOR;

AUTOIMMUNE DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG POTENTIATION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; NEOPLASMS; NUCLEIC ACIDS; NUCLEOSIDES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VIRUS DISEASES;

EID: 84870189452     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules171113503     Document Type: Review

References (159)

1. Janeway, C.A., Jr.; Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20, 197-216.
2. Yoneyama, M.; Fujita, T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol. Rev. 2009, 227, 54-65.
3. Kawai, T.; Akira, S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 2009, 21, 317-337.
4. Ronald, P.C.; Beutler, B. Plant and animal sensors of conserved microbial signatures. Science 2010, 330, 1061-1064.
5. Iwasaki, A.; Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327, 291-295.
6. Basith, S.; Manavalan, B.; Yoo, T.H.; Kim, S.G.; Choi, S. Roles of Toll-like receptors in Cancer: A double-edged sword for defense and offense. Arch. Pharm. Res. 2012, 35, 1297-1316.
7. Manavalan, B.; Basith, S.; Choi, S. Similar Structures but Different Roles - An Updated Perspective on TLR Structures. Front. Physiol. 2011, 2011, 41.
8. Basith, S.; Manavalan, B.; Govindaraj, R.G.; Choi, S. In silico approach to inhibition of signaling pathways of Toll-like receptors 2 and 4 by ST2L. PLoS One 2011, 6, e23989.
9. Krishnan, J.; Lee, G.; Choi, S. Drugs targeting Toll-like receptors. Arch. Pharm. Res. 2009, 32, 1485-1502.
10. Krishnan, J.; Selvarajoo, K.; Tsuchiya, M.; Lee, G.; Choi, S. Toll-like receptor signal transduction. Exp. Mol. Med. 2007, 39, 421-438.
11. Govindaraj, R.G.; Manavalan, B.; Lee, G.; Choi, S. Molecular modeling-based evaluation of hTLR10 and identification of potential ligands in Toll-like receptor signaling. PLoS One 2010, 5, e12713.
12. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 2010, 11, 373-384.
13. Hayashi, F.; Smith, K.D.; Ozinsky, A.; Hawn, T.R.; Yi, E.C.; Goodlett, D.R.; Eng, J.K.; Akira, S.; Underhill, D.M.; Aderem, A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410, 1099-1103.
14. Schwandner, R.; Dziarski, R.; Wesche, H.; Rothe, M.; Kirschning, C.J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J. Biol. Chem. 1999, 274, 17406-17409.
15. Aliprantis, A.O.; Yang, R.B.; Mark, M.R.; Suggett, S.; Devaux, B.; Radolf, J.D.; Klimpel, G.R.; Godowski, P.; Zychlinsky, A. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 1999, 285, 736-739.
16. Takeuchi, O.; Hoshino, K.; Kawai, T.; Sanjo, H.; Takada, H.; Ogawa, T.; Takeda, K.; Akira, S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999, 11, 443-451.
17. Picker, L.J.; Butcher, E.C. Physiological and molecular mechanisms of lymphocyte homing. Annu. Rev. Immunol. 1992, 10, 561-591.
18. Blander, J.M.; Medzhitov, R. Regulation of phagosome maturation by signals from Toll-like receptors. Science 2004, 304, 1014-1018.
19. Oldenburg, M.; Kruger, A.; Ferstl, R.; Kaufmann, A.; Nees, G.; Sigmund, A.; Bathke, B.; Lauterbach, H.; Suter, M.; Dreher, S.; et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 2012, 337, 1111-1115.
20. Leadbetter, E.A.; Rifkin, I.R.; Hohlbaum, A.M.; Beaudette, B.C.; Shlomchik, M.J.; Marshak-Rothstein, A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416, 603-607.
21. Viglianti, G.A.; Lau, C.M.; Hanley, T.M.; Miko, B.A.; Shlomchik, M.J.; Marshak-Rothstein, A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003, 19, 837-847.
22. Krieg, A.M. A role for Toll in autoimmunity. Nat. Immunol. 2002, 3, 423-424.
23. Baccala, R.; Hoebe, K.; Kono, D.H.; Beutler, B.; Theofilopoulos, A.N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat. Med. 2007, 13, 543-51.
24. Miyake, K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol. 2007, 19, 3-10.
25. Zhu, J.; Brownlie, R.; Liu, Q.; Babiuk, L.A.; Potter, A.; Mutwiri, G.K. Characterization of bovine Toll-like receptor 8: Ligand specificity, signaling essential sites and dimerization. Mol. Immunol. 2009, 46, 978-990.
26. Medzhitov, R.; Preston-Hurlburt, P.; Kopp, E.; Stadlen, A.; Chen, C.; Ghosh, S.; Janeway, C.A., Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 1998, 2, 253-258.
27. Takeda, K.; Akira, S. TLR signaling pathways. Semin. Immunol. 2004, 16, 3-9.
28. Suzuki, N.; Suzuki, S.; Duncan, G.S.; Millar, D.G.; Wada, T.; Mirtsos, C.; Takada, H.; Wakeham, A.; Itie, A.; Li, S.; et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 2002, 416, 750-756.
29. Kawagoe, T.; Sato, S.; Matsushita, K.; Kato, H.; Matsui, K.; Kumagai, Y.; Saitoh, T.; Kawai, T.; Takeuchi, O.; Akira, S. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat. Immunol. 2008, 9, 684-691.
30. Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell 2006, 124, 783-801.
31. Kawai, T.; Akira, S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 2005, 17, 338-344.
32. O'Neill, L.A. How Toll-like receptors signal: What we know and what we don't know. Curr. Opin. Immunol. 2006, 18, 3-9.
33. Hoebe, K.; Du, X.; Georgel, P.; Janssen, E.; Tabeta, K.; Kim, S.O.; Goode, J.; Lin, P.; Mann, N.; Mudd, S.; et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003, 424, 743-748.
34. Fitzgerald, K.A.; McWhirter, S.M.; Faia, K.L.; Rowe, D.C.; Latz, E.; Golenbock, D.T.; Coyle, A.J.; Liao, S.M.; Maniatis, T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 2003, 4, 491-496.
35. Pandey, S.; Agrawal, D.K. Immunobiology of Toll-like receptors: Emerging trends. Immunol. Cell Biol. 2006, 84, 333-341.
36. Lee, M.S.; Kim, Y.J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem. 2007, 76, 447-480.
37. Matsumoto, M.; Funami, K.; Tanabe, M.; Oshiumi, H.; Shingai, M.; Seto, Y.; Yamamoto, A.; Seya, T. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 2003, 171, 3154-3162.
38. Latz, E.; Schoenemeyer, A.; Visintin, A.; Fitzgerald, K.A.; Monks, B.G.; Knetter, C.F.; Lien, E.; Nilsen, N.J.; Espevik, T.; Golenbock, D.T. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 2004, 5, 190-198.
39. Hacker, H.; Mischak, H.; Miethke, T.; Liptay, S.; Schmid, R.; Sparwasser, T.; Heeg, K.; Lipford, G.B.; Wagner, H. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 1998, 17, 6230-6240.
40. Nishiya, T.; Kajita, E.; Miwa, S.; Defranco, A.L. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J. Biol. Chem. 2005, 280, 37107-37117.
41. Kim, Y.M.; Brinkmann, M.M.; Paquet, M.E.; Ploegh, H.L. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 2008, 452, 234-238.
42. Brinkmann, M.M.; Spooner, E.; Hoebe, K.; Beutler, B.; Ploegh, H.L.; Kim, Y.M. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J. Cell Biol. 2007, 177, 265-275.
43. Wang, J.; Shao, Y.; Bennett, T.A.; Shankar, R.A.; Wightman, P.D.; Reddy, L.G. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J. Biol. Chem. 2006, 281, 37427-37434.
44. Tabeta, K.; Hoebe, K.; Janssen, E.M.; Du, X.; Georgel, P.; Crozat, K.; Mudd, S.; Mann, N.; Sovath, S.; Goode, J.; et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol. 2006, 7, 156-164.
45. Casrouge, A.; Zhang, S.Y.; Eidenschenk, C.; Jouanguy, E.; Puel, A.; Yang, K.; Alcais, A.; Picard, C.; Mahfoufi, N.; Nicolas, N.; et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006, 314, 308-312.
46. Yang, Y.; Liu, B.; Dai, J.; Srivastava, P.K.; Zammit, D.J.; Lefrancois, L.; Li, Z. Heat shock protein gp96 is a master chaperone for Toll-like receptors and is important in the innate function of macrophages. Immunity 2007, 26, 215-226.
47. Takahashi, K.; Shibata, T.; Akashi-Takamura, S.; Kiyokawa, T.; Wakabayashi, Y.; Tanimura, N.; Kobayashi, T.; Matsumoto, F.; Fukui, R.; Kouro, T.; et al. A protein associated with Toll-like receptor (TLR) 4 (PRAT4A) is required for TLR-dependent immune responses. J. Exp. Med. 2007, 204, 2963-2976.
48. Ewald, S.E.; Lee, B.L.; Lau, L.; Wickliffe, K.E.; Shi, G.P.; Chapman, H.A.; Barton, G.M. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456, 658-662.
49. Asagiri, M.; Hirai, T.; Kunigami, T.; Kamano, S.; Gober, H.J.; Okamoto, K.; Nishikawa, K.; Latz, E.; Golenbock, D.T.; Aoki, K.; et al. Cathepsin K-dependent Toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008, 319, 624-627.
50. Matsumoto, F.; Saitoh, S.; Fukui, R.; Kobayashi, T.; Tanimura, N.; Konno, K.; Kusumoto, Y.; Akashi-Takamura, S.; Miyake, K. Cathepsins are required for Toll-like receptor 9 responses. Biochem. Biophys. Res. Commun. 2008, 367, 693-699.
51. Sepulveda, F.E.; Maschalidi, S.; Colisson, R.; Heslop, L.; Ghirelli, C.; Sakka, E.; Lennon-Dumenil, A.M.; Amigorena, S.; Cabanie, L.; Manoury, B. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 2009, 31, 737-748.
52. Park, B.; Brinkmann, M.M.; Spooner, E.; Lee, C.C.; Kim, Y.M.; Ploegh, H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat. Immunol. 2008, 9, 1407-1414.
53. Peter, M.E.; Kubarenko, A.V.; Weber, A.N.; Dalpke, A.H. Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. J. Immunol. 2009, 182, 7690-7697.
54. Garcia-Cattaneo, A.; Gobert, F.X.; Muller, M.; Toscano, F.; Flores, M.; Lescure, A.; del Nery, E.; Benaroch, P. Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. Proc. Natl. Acad. Sci. USA 2012, 109, 9053-9058.
55. Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 357, 539-545.
56. Marshall-Clarke, S.; Downes, J.E.; Haga, I.R.; Bowie, A.G.; Borrow, P.; Pennock, J.L.; Grencis, R.K.; Rothwell, P. Polyinosinic acid is a ligand for Toll-like receptor 3. J. Biol. Chem. 2007, 282, 24759-24766.
57. Daffis, S.; Samuel, M.A.; Suthar, M.S.; Gale, M., Jr.; Diamond, M.S. Toll-like receptor 3 has a protective role against West Nile virus infection. J. Virol. 2008, 82, 10349-10358.
58. Zhang, S.Y.; Jouanguy, E.; Ugolini, S.; Smahi, A.; Elain, G.; Romero, P.; Segal, D.; Sancho-Shimizu, V.; Lorenzo, L.; Puel, A.; et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317, 1522-7152.
59. Hardarson, H.S.; Baker, J.S.; Yang, Z.; Purevjav, E.; Huang, C.H.; Alexopoulou, L.; Li, N.; Flavell, R.A.; Bowles, N.E.; Vallejo, J.G. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H251-H258.
60. Tabeta, K.; Georgel, P.; Janssen, E.; Du, X.; Hoebe, K.; Crozat, K.; Mudd, S.; Shamel, L.; Sovath, S.; Goode, J.; et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 2004, 101, 3516-3521.
61. Salaun, B.; Coste, I.; Rissoan, M.C.; Lebecque, S.J.; Renno, T. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 2006, 176, 4894-4901.
62. Salem, M.L.; El-Naggar, S.A.; Kadima, A.; Gillanders, W.E.; Cole, D.J. The adjuvant effects of the Toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 2006, 24, 5119-5132.
63. Tewari, K.; Flynn, B.J.; Boscardin, S.B.; Kastenmueller, K.; Salazar, A.M.; Anderson, C.A.; Soundarapandian, V.; Ahumada, A.; Keler, T.; Hoffman, S.L.; et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010, 28, 7256-7266.
64. Zheng, R.; Cohen, P.A.; Paustian, C.A.; Johnson, T.D.; Lee, W.T.; Shu, S.; Koski, G.K. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res. 2008, 68, 4045-4049.
65. Longhi, M.P.; Trumpfheller, C.; Idoyaga, J.; Caskey, M.; Matos, I.; Kluger, C.; Salazar, A.M.; Colonna, M.; Steinman, R.M. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 2009, 206, 1589-1602.
66. Carter, W.A.; Hubbell, H.R.; Krueger, L.J.; Strayer, D.R. Comparative studies of ampligen (mismatched double-stranded RNA) and interferons. J. Biol. Response Mod. 1985, 4, 613-620.
67. Hubbell, H.R.; Pequignot, E.C.; Todd, J.; Raymond, L.C.; Mayberry, S.D.; Carter, W.A.; Strayer, D.R. Augmented antitumor effect of combined human natural interferon-alpha and mismatched double-stranded RNA treatment against a human malignant melanoma xenograft. J. Biol. Response Mod. 1987, 6, 525-536.
68. Shime, H.; Matsumoto, M.; Oshiumi, H.; Tanaka, S.; Nakane, A.; Iwakura, Y.; Tahara, H.; Inoue, N.; Seya, T. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc. Natl. Acad. Sci. USA 2012, 109, 2066-2071.
69. Akazawa, T.; Ebihara, T.; Okuno, M.; Okuda, Y.; Shingai, M.; Tsujimura, K.; Takahashi, T.; Ikawa, M.; Okabe, M.; Inoue, N.; et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. USA 2007, 104, 252-257.
70. Navabi, H.; Jasani, B.; Reece, A.; Clayton, A.; Tabi, Z.; Donninger, C.; Mason, M.; Adams, M. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009, 27, 107-115.
71. Strayer, D.R.; Carter, W.A.; Stouch, B.C.; Stevens, S.R.; Bateman, L.; Cimoch, P.J.; Lapp, C.W.; Peterson, D.L.; Mitchell, W.M. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One 2012, 7, e31334.
72. Shir, A.; Ogris, M.; Roedl, W.; Wagner, E.; Levitzki, A. EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin. Cancer Res. 2011, 17, 1033-1043.
73. Wang, L.; Smith, D.; Bot, S.; Dellamary, L.; Bloom, A.; Bot, A. Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J. Clin. Invest. 2002, 110, 1175-1184.
74. Sugiyama, T.; Hoshino, K.; Saito, M.; Yano, T.; Sasaki, I.; Yamazaki, C.; Akira, S.; Kaisho, T. Immunoadjuvant effects of polyadenylic: polyuridylic acids through TLR3 and TLR7. Int. Immunol. 2008, 20, 1-9.
75. Conforti, R.; Ma, Y.; Morel, Y.; Paturel, C.; Terme, M.; Viaud, S.; Ryffel, B.; Ferrantini, M.; Uppaluri, R.; Schreiber, R.; et al. Opposing effects of Toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 2010, 70, 490-500.
76. Laplanche, A.; Alzieu, L.; Delozier, T.; Berlie, J.; Veyret, C.; Fargeot, P.; Luboinski, M.; Lacour, J. Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: A 14 year follow-up analysis of a randomized trial of the Federation Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res. Treat. 2000, 64, 189-191.
77. Jeung, H.C.; Moon, Y.W.; Rha, S.Y.; Yoo, N.C.; Roh, J.K.; Noh, S.H.; Min, J.S.; Kim, B.S.; Chung, H.C. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: Final results of 15-year follow-up. Ann. Oncol. 2008, 19, 520-526.
78. Lacour, J.; Laplanche, A.; Malafosse, M.; Gallot, D.; Julien, M.; Rotman, N.; Guivarc'h, M.; Roullet-Audy, J.C.; Lasser, P.; Hautefeuille, P.; et al. Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: A 6 1/2 year follow-up analysis of a multicentric double blind randomized trial. Eur. J. Surg. Oncol. 1992, 18, 599-604.
79. Levy, H.B.; Baer, G.; Baron, S.; Buckler, C.E.; Gibbs, C.J.; Iadarola, M.J.; London, W.T.; Rice, J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis. 1975, 132, 434-439.
80. Hawkins, M.J.; Levin, M.; Borden, E.C. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J. Biol. Response Mod. 1985, 4, 664-668.
81. Hennessy, E.J.; Parker, A.E.; O'Neill, L.A. Targeting Toll-like receptors: Emerging therapeutics? Nat. Rev. Drug Discov. 2010, 9, 293-307.
82. Panter, G.; Kuznik, A.; Jerala, R. Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr. Opin. Mol. Ther. 2009, 11, 133-145.
83. ClinicalTrials.gov. Available online: http://clinicaltrials.gov/ (accessed on 15 August 2012).
84. Diebold, S.S.; Kaisho, T.; Hemmi, H.; Akira, S.; Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303, 1529-1531.
85. Heil, F.; Hemmi, H.; Hochrein, H.; Ampenberger, F.; Kirschning, C.; Akira, S.; Lipford, G.; Wagner, H.; Bauer, S. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004, 303, 1526-1529.
86. Forsbach, A.; Samulowitz, U.; Volp, K.; Hofmann, H.P.; Noll, B.; Tluk, S.; Schmitz, C.; Wader, T.; Muller, C.; Podszuweit, A.; et al. Dual or triple activation of TLR7, TLR8, and/or TLR9 by single-stranded oligoribonucleotides. Nucleic Acid Ther. 2011, 21, 423-436.
87. Lund, J.M.; Alexopoulou, L.; Sato, A.; Karow, M.; Adams, N.C.; Gale, N.W.; Iwasaki, A.; Flavell, R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 2004, 101, 5598-5603.
88. Forsbach, A.; Nemorin, J.G.; Montino, C.; Muller, C.; Samulowitz, U.; Vicari, A.P.; Jurk, M.; Mutwiri, G.K.; Krieg, A.M.; Lipford, G.B.; et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol. 2008, 180, 3729-2738.
89. Jurk, M.; Heil, F.; Vollmer, J.; Schetter, C.; Krieg, A.M.; Wagner, H.; Lipford, G.; Bauer, S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 2002, 3, 499.
90. Demaria, O.; Pagni, P.P.; Traub, S.; de Gassart, A.; Branzk, N.; Murphy, A.J.; Valenzuela, D.M.; Yancopoulos, G.D.; Flavell, R.A.; Alexopoulou, L. TLR8 deficiency leads to autoimmunity in mice. J. Clin. Invest. 2010, 120, 3651-3662.
91. Imbertson, L.M.; Beaurline, J.M.; Couture, A.M.; Gibson, S.J.; Smith, R.M.; Miller, R.L.; Reiter, M.J.; Wagner, T.L.; Tomai, M.A. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest. Dermatol. 1998, 110, 734-739.
92. Reiter, M.J.; Testerman, T.L.; Miller, R.L.; Weeks, C.E.; Tomai, M.A. Cytokine induction in mice by the immunomodulator imiquimod. J. Leukoc. Biol. 1994, 55, 234-240.
93. Testerman, T.L.; Gerster, J.F.; Imbertson, L.M.; Reiter, M.J.; Miller, R.L.; Gibson, S.J.; Wagner, T.L.; Tomai, M.A. Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukoc. Biol. 1995, 58, 365-372.
94. Miller, R.L.; Gerster, J.F.; Owens, M.L.; Slade, H.B.; Tomai, M.A. Review Article Imiquimod applied topically: A novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 1999, 21, 1-14.
95. Miller, R.L.; Meng, T.C.; Tomai, M.A. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 2008, 21, 69-87.
96. Wagner, T.L.; Ahonen, C.L.; Couture, A.M.; Gibson, S.J.; Miller, R.L.; Smith, R.M.; Reiter, M.J.; Vasilakos, J.P.; Tomai, M.A. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 1999, 191, 10-19.
97. Bernstein, D.I.; Harrison, C.J.; Tomai, M.A.; Miller, R.L. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J. Infect. Dis. 2001, 183, 844-849.
98. Schon, M.P.; Schon, M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008, 27, 190-199.
99. Pockros, P.J.; Guyader, D.; Patton, H.; Tong, M.J.; Wright, T.; McHutchison, J.G.; Meng, T.C. Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol. 2007, 47, 174-182.
100. Butchi, N.B.; Pourciau, S.; Du, M.; Morgan, T.W.; Peterson, K.E. Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: Comparison of multiple TLR7 and/or TLR8 agonists. J. Immunol. 2008, 180, 7604-7612.
101. Salio, M.; Speak, A.O.; Shepherd, D.; Polzella, P.; Illarionov, P.A.; Veerapen, N.; Besra, G.S.; Platt, F.M.; Cerundolo, V. Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc. Natl. Acad. Sci. USA 2007, 104, 20490-20495.
102. Dummer, R.; Hauschild, A.; Becker, J.C.; Grob, J.J.; Schadendorf, D.; Tebbs, V.; Skalsky, J.; Kaehler, K.C.; Moosbauer, S.; Clark, R.; et al. An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 2008, 14, 856-864.
103. Gorden, K.B.; Gorski, K.S.; Gibson, S.J.; Kedl, R.M.; Kieper, W.C.; Qiu, X.; Tomai, M.A.; Alkan, S.S.; Vasilakos, J.P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 2005, 174, 1259-1268.
104. Velasquez, L.S.; Hjelm, B.E.; Arntzen, C.J.; Herbst-Kralovetz, M.M. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin. Vaccine Immunol. 2010, 17, 1850-1858.
105. Pope, B.L.; Sigindere, J.; Chourmouzis, E.; MacIntyre, P.; Goodman, M.G. 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine. Cancer Immunol. Immunother. 1994, 38, 83-91.
106. Heil, F.; Ahmad-Nejad, P.; Hemmi, H.; Hochrein, H.; Ampenberger, F.; Gellert, T.; Dietrich, H.; Lipford, G.; Takeda, K.; Akira, S.; et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol. 2003, 33, 2987-2997.
107. Lee, J.; Chuang, T.H.; Redecke, V.; She, L.; Pitha, P.M.; Carson, D.A.; Raz, E.; Cottam, H.B. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 2003, 100, 6646-6651.
108. Kang, S.S.; Kauls, L.S.; Gaspari, A.A. Toll-like receptors: Applications to dermatologic disease. J. Am. Acad. Dermatol. 2006, 54, 951-983.
109. Sarosdy, M.F. A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. Eur. Urol. 1997, 31 (Suppl. 1), 20-26.
110. Tei, Y.; Matsuyama, H.; Wada, T.; Kurisu, H.; Tahara, M.; Naito, K. In vitro antitumor activity of bropirimine against urinary bladder tumor cells. Anticancer Res. 2002, 22, 1667-1671.
111. Lee, J.; Wu, C.C.; Lee, K.J.; Chuang, T.H.; Katakura, K.; Liu, Y.T.; Chan, M.; Tawatao, R.; Chung, M.; Shen, C.; et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 2006, 103, 1828-1833.
112. Horsmans, Y.; Berg, T.; Desager, J.P.; Mueller, T.; Schott, E.; Fletcher, S.P.; Steffy, K.R.; Bauman, L.A.; Kerr, B.M.; Averett, D.R. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005, 42, 724-731.
113. Fletcher, S.; Steffy, K.; Averett, D. Masked oral prodrugs of Toll-like receptor 7 agonists: A new approach for the treatment of infectious disease. Curr. Opin. Investig. Drugs 2006, 7, 702-708.
114. Kronenberger, B.; Zeuzem, S. Current and future treatment options for HCV. Ann. Hepatol. 2009, 8, 103-112.
115. Kaisho, T.; Akira, S. Toll-like receptor function and signaling. J. Allergy Clin. Immunol. 2006, 117, 979-987.
116. Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K.; et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408, 740-745.
117. Krieg, A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006, 5, 471-484.
118. Barton, G.M.; Kagan, J.C.; Medzhitov, R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 2006, 7, 49-56.
119. Carpentier, A.; Laigle-Donadey, F.; Zohar, S.; Capelle, L.; Behin, A.; Tibi, A.; Martin-Duverneuil, N.; Sanson, M.; Lacomblez, L.; Taillibert, S.; et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol. 2006, 8, 60-66.
120. Vollmer, J.; Krieg, A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009, 61, 195-204.
121. Agrawal, S.; Kandimalla, E.R. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem. Soc. Trans. 2007, 35, 1461-1467.
122. Wang, D.; Li, Y.; Yu, D.; Song, S.S.; Kandimalla, E.R.; Agrawal, S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int. J. Oncol. 2004, 24, 901-908.
123. Kline, J.N.; Krieg, A.M. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008, 21, 434-439.
124. Kochling, J.; Prada, J.; Bahrami, M.; Stripecke, R.; Seeger, K.; Henze, G.; Wittig, B.; Schmidt, M. Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 2008, 26, 4669-4675.
125. Horner, A.A.; Widhopf, G.F.; Burger, J.A.; Takabayashi, K.; Cinman, N.; Ronaghy, A.; Spiegelberg, H.L.; Raz, E. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J. Allergy Clin. Immunol. 2001, 108, 417-423.
126. Rakoff-Nahoum, S.; Medzhitov, R. Toll-like receptors and cancer. Nat. Rev. Cancer 2009, 9, 57-63.
127. Barry, M.; Cooper, C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin. Biol. Ther. 2007, 7, 1731-1737.
128. Data From Two Phase 3 Studies Demonstrate HEPLISAV's Superiority in Immunizing Persons With Diabetes From Hepatitis B. Available online: http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=260991 (accessed on 28 August 2012).
129. Harandi, A.M.; Davies, G.; Olesen, O.F. Vaccine adjuvants: Scientific challenges and strategic initiatives. Expert Rev. Vaccines 2009, 8, 293-298.
130. Hepatitis C. Available online: http://www.dynavax.com/hepatitis-ct.html (accessed on 28 August 2012).
131. Krieg, A.M.; Yi, A.K.; Matson, S.; Waldschmidt, T.J.; Bishop, G.A.; Teasdale, R.; Koretzky, G.A.; Klinman, D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374, 546-549.
132. Manegold, C.; Gravenor, D.; Woytowitz, D.; Mezger, J.; Hirsh, V.; Albert, G.; Al-Adhami, M.; Readett, D.; Krieg, A.M.; Leichman, C.G. Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008, 26, 3979-3986.
133. Zent, C.S.; Smith, B.J.; Ballas, Z.K.; Wooldridge, J.E.; Link, B.K.; Call, T.G.; Shanafelt, T.D.; Bowen, D.A.; Kay, N.E.; Witzig, T.E.; et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk. Lymphoma 2012, 53, 211-217.
134. Dorn, A.; Kippenberger, S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr. Opin. Mol. Ther. 2008, 10, 10-20.
135. Heijink, I.H.; van Oosterhout, A.J. Strategies for targeting T-cells in allergic diseases and asthma. Pharmacol. Ther. 2006, 112, 489-500.
136. Pastorelli, L.; Pizarro, T.T.; Cominelli, F.; Vecchi, M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin. Emerg. Drugs 2009, 14, 505-521.
137. Vollmer, J.; Tluk, S.; Schmitz, C.; Hamm, S.; Jurk, M.; Forsbach, A.; Akira, S.; Kelly, K.M.; Reeves, W.H.; Bauer, S.; et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 2005, 202, 1575-1585.
138. Christensen, S.R.; Shupe, J.; Nickerson, K.; Kashgarian, M.; Flavell, R.A.; Shlomchik, M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25, 417-428.
139. Sun, S.; Rao, N.L.; Venable, J.; Thurmond, R.; Karlsson, L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets 2007, 6, 223-235.
140. Parkinson, T. The future of Toll-like receptor therapeutics. Curr. Opin. Mol. Ther. 2008, 10, 21-31.
141. Autoimmune. Available online: http://www.iderapharma.com/clinical/ autoimmune.html (accessed on 12 September 2012).
142. Barrat, F.J.; Meeker, T.; Chan, J.H.; Guiducci, C.; Coffman, R.L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007, 37, 3582-3586.
143. Pawar, R.D.; Ramanjaneyulu, A.; Kulkarni, O.P.; Lech, M.; Segerer, S.; Anders, H.J. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol. 2007, 18, 1721-1731.
144. Napirei, M.; Karsunky, H.; Zevnik, B.; Stephan, H.; Mannherz, H.G.; Moroy, T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 2000, 25, 177-181.
145. Yasutomo, K.; Horiuchi, T.; Kagami, S.; Tsukamoto, H.; Hashimura, C.; Urushihara, M.; Kuroda, Y. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 2001, 28, 313-314.
146. Lau, C.M.; Broughton, C.; Tabor, A.S.; Akira, S.; Flavell, R.A.; Mamula, M.J.; Christensen, S.R.; Shlomchik, M.J.; Viglianti, G.A.; Rifkin, I.R.; et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 2005, 202, 1171-1177.
147. Hooks, J.J.; Moutsopoulos, H.M.; Geis, S.A.; Stahl, N.I.; Decker, J.L.; Notkins, A.L. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 1979, 301, 5-8.
148. Ytterberg, S.R.; Schnitzer, T.J. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982, 25, 401-406.
149. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389-395.
150. Lovgren, T.; Eloranta, M.L.; Bave, U.; Alm, G.V.; Ronnblom, L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004, 50, 1861-1872.
151. Stott, K.; Tang, G.S.; Lee, K.B.; Thomas, J.O. Structure of a complex of tandem HMG boxes and DNA. J. Mol. Biol. 2006, 360, 90-104.
152. Jego, G.; Palucka, A.K.; Blanck, J.P.; Chalouni, C.; Pascual, V.; Banchereau, J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19, 225-234.
153. Izui, S.; Iwamoto, M.; Fossati, L.; Merino, R.; Takahashi, S.; Ibnou-Zekri, N. The Yaa gene model of systemic lupus erythematosus. Immunol. Rev. 1995, 144, 137-156.
154. Deng, G.M.; Nilsson, I.M.; Verdrengh, M.; Collins, L.V.; Tarkowski, A. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat. Med. 1999, 5, 702-705.
155. Prinz, M.; Garbe, F.; Schmidt, H.; Mildner, A.; Gutcher, I.; Wolter, K.; Piesche, M.; Schroers, R.; Weiss, E.; Kirschning, C.J.; et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 2006, 116, 456-464.
156. Wu, H.J.; Sawaya, H.; Binstadt, B.; Brickelmaier, M.; Blasius, A.; Gorelik, L.; Mahmood, U.; Weissleder, R.; Carulli, J.; Benoist, C.; et al. Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk. J. Exp. Med. 2007, 204, 1911-1922.
157. Cherfils-Vicini, J.; Platonova, S.; Gillard, M.; Laurans, L.; Validire, P.; Caliandro, R.; Magdeleinat, P.; Mami-Chouaib, F.; Dieu-Nosjean, M. C.; Fridman, W. H.; et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest. 2010, 120, 1285-1297.
158. Chiron, D.; Pellat-Deceunynck, C.; Amiot, M.; Bataille, R.; Jego, G. TLR3
159. Gorden, K.K.; Qiu, X.X.; Binsfeld, C.C.; Vasilakos, J.P.; Alkan, S.S. Cutting edge: Activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol. 2006, 177, 6584-6587.